The professor of neurology in the department of neuroscience at Monash University discussed implementation strategies for treatment approaches to achieve seizure freedom in patients with epilepsy. [WATCH TIME: 5 minutes]
The assistant professor of neurology and neurosurgery at McGill University discussed the role of paramagnetic rim lesions as potential biomarkers of compartmentalized inflammation in MS. [WATCH TIME: 4 minutes]
The chief of headache at UT Austin Dell Children’s Hospital provided insight on a new series designed to deliver longitudinal comprehensive pediatric headache education. [WATCH TIME: 3 minutes]
The director of the Women’s Alzheimer’s Movement Preventer Center at Cleveland Clinic provided perspective on the possibility of gender-specific therapies to overcome disparities in Alzheimer disease. [WATCH TIME: 3 minutes]
The professor of medicine and clinical translational science at the University of Pittsburgh provided commentary on the mechanism and clinical value of AD109, a novel combination therapy for OSA, following positive phase 3 SynAIRgy trial results. [WATCH TIME: 7 minutes]
The assistant professor of neurosurgery and biomedical informatics at the State University of New York at Buffalo talked about the efficacy and safety of using embolization as a promising treatment for subdural hematomas. [WATCH TIME: 3 minutes]
Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, talk about the factors to consider when determining whether patients are candidates for anti-CD20 therapies.
The vice president of the Rare Disease Translational Center at the Jackson Laboratory discussed results from a recently published study reinforcing stathmin-2 as a potential therapeutic strategy for ALS. [WATCH TIME: 4 minutes]
The chair and vice-chair of the Headache and Facial Pain Section of the American Academy of Neurology provided insight on projects they feel are needed to advance the care of patients with migraine-related disorders. [WATCH TIME: 4 minutes]
The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic talked about findings from a real-world study assessing novel monoclonal antibodies in patients with NMOSD presented at ACTRIMS Forum 2024. [WATCH TIME: 4 minutes]
Plagued by a long history of under- and inadequate treatment, clinicians have more options than ever to craft a personalized, effective plan for their patients.
The neuromuscular specialist at the University of Tennessee Medical Center provided clinical insight on a retrospective analysis studying the long-term corticosteroid patterns of approved treatments for generalized myasthenia gravis. [WATCH TIME: 5 minutes]
The senior consultant for the department of neurology at the National Neuroscience Institute discussed a report on two patients who developed an uncommon adverse event of late-onset neurotropenia after anti-CD20 therapy treatment. [WATCH TIME: 8 minutes]
The research director and staff scientist at Cleveland Clinic’s Epilepsy Center detailed the clinical pre- and post-surgery benefits patients with epilepsy get from MR fingerprinting. [WATCH TIME: 3 minutes]
Jim Cassidy, MD, PhD, chief medical officer at SpringWorks Therapeutics, talked about how the prioritization of mirdametinib, a promising treatment for both adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas.
The professor of neurology at the Miami Miller School of Medicine detailed the clinical potential of Cognivue’s Amyloid Risk Measure (CARM) for identifying individuals with cognitive impairment likely related to amyloid pathology. [WATCH TIME: 5 minutes]
The chairman and chief executive officer at Biomed discussed the additive benefits of combination therapy for Alzheimer disease, providing context on the strengths of different drugs and how it might lead to a more precision medicine approach. [WATCH TIME: 6 minutes]
The neuropathologist at Mount Sinai and chief science officer of Precise Dx pairing spoke to the role of artificial intelligence in the diagnosis of diseases from peripheral tissue biopsies and its ability to improve neuropathology. [WATCH TIME: 8 minutes]
This closing episode looks ahead to the future of SMA care, examining how updated best practices aim to accelerate access, optimize outcomes, and fuel ongoing progress.
L. John Greenfield Jr, MD, PhD, “spoke” about the future of artificial intelligence in neurology with ChatGPT-4—one of the largest language modules that have grabbed the field’s interest.
The vice president of the Rare Disease Translational Center at the Jackson Laboratory provided commentary on the next steps needed to further understand stathmin-2’s role as a potential disease-modifying biomarker. [WATCH TIME: 3 minutes]
Although challenging, shared decision-making is a rewarding part of the practice of medicine. Involving patients in therapeutic decisions can improve patient autonomy and satisfaction—but it is not easy to implement.
The clinical associate professor of neurology at the University of Michigan spoke on the importance of sleep medicine education for trainees, as well as areas that could be improved. [WATCH TIME: 3 minutes]
This is the deck of the article. It can be used to provide further context to the headline and provides search engines with summary text for social posts.
The medical director of the Westport Headache Institute spoke to the role that devices can play in layered and variable treatment approaches, and how this better lends itself to offering personalized treatment to different individuals with migraine
The director of the Allegheny Multiple Sclerosis Treatment Center at Allegheny General Hospital discussed exploring the potential role of BTK inhibitors and advanced MRI techniques to address smoldering multiple sclerosis. [WATCH TIME: 10 minutes]
The assistant professor of neurology at The Ohio State University Wexner Medical Center provided insight on finding strategies to prevent neurodegeneration in multiple sclerosis. [WATCH TIME: 3 minutes]
The assistant professor of neurology at Robert Wood Johnson Medical School talked about a collaborative initiative that aims to address AD disparities in Asian and Pacific Islander American populations. [WATCH TIME: 3 minutes]
In this episode of MEDcast, expert neurologists delve into anti-CD20 disease modifying therapies (DMTs) in MS. They assess the correlation between clinical observations and immunological processes in MS patients, and also examine the role of the Epstein Barr virus in MS.
Evan L. Smith, PhD, assistant professor of Physical Medicine & Rehabilitation at University of Michigan, discussed how emotional wellbeing, motivation, and evidence-based therapies can significantly influence outcomes in MS.